



COMBINED SOLUTIONS FOR INDUSTRY

NCS AMERICA Inc. | PRESS RELEASE

NCS America Inc. Launches the Shoulder Pacemaker™ after receiving FDA clearance

NCS America, Inc. a world leader in developing technology to help diagnose, treat and prevent musculoskeletal injuries, today announced the expansion of their breakthrough product offerings with the FDA clearance of the Shoulder Pacemaker™ and its patented **Motion Activated Stimulation (MAS) technology**.

The Shoulder Pacemaker™ is an NMES device designed for use in muscle re-education, maintaining or increasing range of motion, and in the prevention or retardation of disuse atrophy.

"Motion activated stimulation is taking NMES to a new level!" said Matteo Mantovani, CEO and technical director of NCS. *"This product advances NMES therapy with the ability to deliver stimulation with precision and accuracy in order to help re-educate imbalance muscular activity in the shoulder, stimulation controlled by movement means restoring the right muscles recruitment pattern. In addition to this, automatic remote monitoring and reporting, checking both for the patient's compliance and evolution, represent a significant benefit for patients and healthcare providers."*

John Winslow, CEO of NCS America, Inc. says *"We are very pleased to receive the FDA clearance of the of the Shoulder Pacemaker™ which provides an exciting extension to the NCS product portfolio for the United States market. NCS experience in Europe has proven that the market's interest in motion activated muscle stimulation (MAS) is far beyond our original expectations. We are happy to make the device available in the U.S. to caregivers whose patients will benefit from this technology."*

NCS America, Inc.

NCS America, Inc. is the U.S. headquarter of NCS, a global medical device company focused on upper extremity and orthopedic pathologies. With our deep understanding and experience in the biomechanics of the shoulder we design, manufacture and market technology that assists caregivers in the diagnosis, treatment and prevention of orthopedic injuries.

With operational headquarters in Carpi, Italy and in the U.S. in Denver, Colorado, NCS's products are sold in over 20 countries via the Company's sales representatives and distributors. For more information on the Company, please visit www.ncs-company.com.

NCS America, Inc. – Contact Reference

John Winslow

CEO - NCS America, Inc.

j.winslow@ncs-company.com

970-980-1110

Craig Kramer

VP of Business Development - NCS America, Inc.

c.kramer@ncs-company.com

317-441-4289

Forward-Looking Statements

This communication contains forward-looking statements.

Any or all forward-looking statements that we make may turn out to be wrong (due to inaccurate assumptions that we make or otherwise), and our actual outcomes and results may differ materially from those expressed in these forward-looking statements. You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We undertake no obligation to update, and expressly disclaim any duty to update, our forward-looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise.

Newcast Services srl Via Pola Esterna 4/11 41012 Carpi Tel e Fax: +39 059669813 VAT No. IT02877880365	NCS Lab srl Via Pola Esterna 4/12 41012 Carpi (MO) - IT Tel e Fax: +39 059669813 VAT No. IT02550041202	NCS Lab srl – Regional Office Via Ducezio n.16 98124 Messina (ME) - IT Tel e Fax: +39 059669813 VAT No. IT02550041202	Ncs Company Spa Via Pola Esterna 4/11 41012 Carpi (MO) - IT Tel e Fax: +39 059669813 VAT No. IT03196540367	NCS America Inc - USA 3500 South Dupont Highway Dover DE 19901(Kent) - USA Tel: +1 212 8251003 EIN: 82-4058961
--	---	--	---	---